Generic Zepbound and Mounjaro: Is There One Yet? Patents, Filings and Cheaper Options

Written by Nataliia Bondarchuk. Updated October 30, 2026.

There is no generic Zepbound or Mounjaro yet. As of October 2026 the FDA has not approved any generic version of tirzepatide, the active ingredient in both drugs, and none is sold anywhere in the world. The first generic applications were filed in mid-2026, and Eli Lilly sued 14 companies in August 2026 to block them. Lilly's main patent on the tirzepatide molecule runs until 2036, and other patents on the formulation and uses run to 2039 and 2041, so unless generic makers win in court or reach settlements, a US generic is most likely years away. What exists today are cheaper legal routes to the brand-name drug, such as LillyDirect's $299 to $449 self-pay prices and Medicare's $50 GLP-1 Bridge, alongside compounded and 'research' products that are not generics and are not approved. This guide sets out the patent timeline, who has filed, what happens next, and how to pay less now.

Yes. Both contain tirzepatide and are made by Eli Lilly. Mounjaro was approved in May 2022 for type 2 diabetes; Zepbound was approved in 2023 for chronic weight management and later for obstructive sleep apnea in adults with obesity. The doses and pens are the same; the difference is the approved use, which decides how insurers cover them. A generic tirzepatide would therefore compete with both brands at once. The details are in Mounjaro vs Zepbound.

Several layers of protection stand in the way of a generic, and each ends at a different time. The dates below come from the patents and exclusivities listed for Zepbound and Mounjaro, and from Lilly's 2025 annual report.

Lilly estimates its compound patent protection at 2036 in the US, 2037 in major European countries and 2040 in Japan. Patent dates are the outer limit, not a prediction: generic makers can launch earlier if a court finds the later patents invalid or not infringed, or if Lilly agrees to a settlement allowing an earlier date.

Generic makers apply to the FDA through an abbreviated new drug application. In June 2026 the FDA accepted two tirzepatide applications from Sandoz for review, and the Chinese company Hybio announced filings that challenge Lilly's patents. On August 7, 2026, Lilly sued 14 filers in federal court in Delaware, including Sandoz, MSN, Biocon, Zydus, Dr. Reddy's, Hikma and Hybio, asserting nine patents, including the compound patent. Under US law, a patent lawsuit filed promptly after such a challenge automatically delays FDA approval of the generic while the case proceeds, typically for many months to years, unless the court rules sooner. Patent cases of this kind often end in settlements that set a licensed launch date. None has been announced.

A generic. Tirzepatide is a synthetic peptide approved as a drug under new drug applications, not as a biological product, and the companies challenging it have used the generic-drug pathway. That means a future copy would be a true generic, rated as interchangeable by the FDA if it meets the standards, rather than a biosimilar. Why tirzepatide is classed as a peptide drug is explained in is tirzepatide a peptide.

Not as of October 2026. Reports from mid-2026 state that no generic tirzepatide has launched anywhere. India, where generic semaglutide went on sale in March 2026 after its patent expired, does not yet have generic tirzepatide, and Lilly's protection there is expected to last into the mid-2030s. Products marketed online as 'generic Mounjaro from India' or elsewhere are not approved generics.

No. A generic is approved by the FDA after showing it matches the brand-name drug. Compounded tirzepatide is mixed by pharmacies and is not reviewed by the FDA for safety, effectiveness or quality. During the shortage of 2022 to 2024, pharmacies were temporarily allowed to make copies. The FDA declared the shortage over on October 2, 2024, confirmed that decision on December 19, 2024, and the grace periods for compounders ended on February 18, 2025 for pharmacies and March 19, 2025 for outsourcing facilities. By May 31, 2026 the FDA had received more than 730 adverse event reports involving compounded tirzepatide.

The KwikPen holds four doses and costs the same as vials through LillyDirect, as explained in Zepbound KwikPen. Stopping because of cost usually means regaining weight, as discussed in what happens when you stop tirzepatide, so it is worth comparing these options before deciding. How the dose ladder affects the price is set out in tirzepatide dosage.

Probably, once several companies compete, but not immediately. Generic drug prices usually fall furthest when multiple manufacturers enter. Lilly has already lowered effective prices through self-pay programs, and competition from semaglutide, whose US list price falls to $675 a month in January 2027, and from new drugs such as Lilly's Foundayo pill is pushing prices down before any generic arrives. How tirzepatide compares with semaglutide is in tirzepatide vs semaglutide, and the drugs coming next are in what comes after tirzepatide.

Until a true generic exists, the price you pay depends on the format and your coverage. Our Zepbound cost guide for 2026 breaks down Lilly's self-pay KwikPen and vial prices, the savings card and the Medicare changes.

There is no generic Zepbound or Mounjaro in 2026. Generic applications were filed this year and are tied up in Lilly's patent lawsuits; the molecule patent runs to 2036 and other patents to 2039 and beyond, so a launch before then would require a court win or a settlement. Compounded and research products are not generics. The realistic ways to pay less today are LillyDirect's self-pay prices, insurance coverage, Mounjaro for diabetes and, for Medicare members, the $50 GLP-1 Bridge. How tirzepatide itself works is explained in how Zepbound works, and Lilly's pill alternative in tirzepatide pill.

This article summarizes public patent, regulatory and pricing information for general information. It is not legal or medical advice.